Anuh Pharma (506260) Q1 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended 30th June 2025 and appointed a new Chief Marketing Officer.

• Financial results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹18,647.94 lakhs, down from ₹19,813.95 lakhs in the previous quarter, but up from ₹13,790.83 lakhs year-over-year.

• Net profit after tax for Q1 FY26 stood at ₹830.12 lakhs, compared to ₹1,245.70 lakhs in the previous quarter and ₹950.91 lakhs in Q1 FY25.

• EBITDA for Q1 FY26 was ₹1,367.94 lakhs (7.34% margin), compared to ₹2,006.92 lakhs (10.13%) in the previous quarter and ₹1,428.81 lakhs (10.36%) year-over-year.

• Basic and diluted EPS for Q1 FY26 was ₹1.66, down from ₹2.49 in the previous quarter and ₹1.90 year-over-year.

Outlook and guidance

• Book closure intimation to be provided in due course; no further forward-looking guidance disclosed.